Baseline Assessment of Circulating MicroRNAs Near Diagnosis of Type 1 Diabetes Predicts Future Stimulated Insulin Secretion

What is it about?

This study reports that circulating microRNAs can serve as biomarkers in type 1 diabetes. Specifically, microRNAs measured shortly after diagnosis can help forecasting the future loss of insulin secretion, for up to one year. Predicting the decline of insulin secretion is useful to advance the efficiency of clinical trials and ultimately to discover effective therapies to halt the disease process and preserve patients’ ability to make their own insulin.

Featured Image